Mitsui Chemicals, Jiksak Pursue Joint Development in Aim of Commercializing Nerve Tissue Generated From Human iPS Cells

Jul 8, 2022

Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) and Jiksak Bioengineering Inc. (Saiwai-ku, Kawasaki; CEO: KAWADA Jiro) have begun joint research aimed at commercializing Nerve Organoids™, which consist of nerve tissue derived from human iPS cells. By taking Mitsui Chemicals’ technology for InnoCell™ cell culture vessels with high oxygen permeability and combining it with Jiksak’s technology relating to the creation of Nerve Organoids™, the partners intend to develop practical technology for simply and efficiently culturing nerve tissue, which is set to become essential in the drug discovery and regenerative medicine sectors, among others.

 

Mitsui Chemicals’s announcement link

https://jp.mitsuichemicals.com/en/release/2022/2022_0708.htm